Massive breast cancer database aims to improve care
NCT ID NCT03275311
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study gathers information from over 42,000 people with metastatic breast cancer treated at 18 French cancer centers since 2008. Researchers will look at how treatments have changed over time and how they affect survival. The goal is to learn from real-world data to improve future care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 42,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2014
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All consecutive patients treated for a metastatic breast cancer in a French Comprehensive Cancer Center over the selection period.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria : * 18 years old patient * Patient receiving chemotherapy, targeted therapy, immunotherapy, radiation therapy and hormonotherapy in a French Comprehensive Cancer Center. Exclusion criteria : None
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
20 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Antoine Lacassagne
RECRUITINGNice, 06189, France
-
Centre Eugène Marquis
RECRUITINGRennes, 35042, France
-
Centre François Baclesse
RECRUITINGCaen, 14076, France
-
Centre Georges-François Leclerc
RECRUITINGDijon, 21079, France
-
Centre Henri Becquerel
RECRUITINGRouen, 76038, France
-
Centre Jean Perrin
RECRUITINGClermont-Ferrand, 63011, France
-
Centre Léon Bérard
RECRUITINGLyon, 69373, France
-
Centre Oscar Lambret
RECRUITINGLille, 59020, France
-
Centre Paul Strauss
RECRUITINGStrasbourg, 67065, France
-
Institut Bergonié
RECRUITINGBordeaux, 33076, France
-
Institut Claudius Regaud
RECRUITINGToulouse, 31059, France
-
Institut Curie
RECRUITINGParis, 75005, France
-
Institut Curie - Hôpital René Huguenin
RECRUITINGSaint-Cloud, 92210, France
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
Institut Jean Godinot
RECRUITINGReims, 51056, France
-
Institut Paoli-Calmettes
RECRUITINGMarseille, 13273, France
-
Institut de Cancérologie de Lorraine
RECRUITINGNancy, France
-
Institut de Cancérologie de l'Ouest - Paul Papin
RECRUITINGAngers, 49933, France
-
Institut de cancérologie de l'Ouest - René Gauducheau
RECRUITINGNantes, 44805, France
-
Institut régional du Cancer Montpellier / Val d'Aurelle
RECRUITINGMontpellier, 34298, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blood test reveal when breast cancer treatment stops working?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Zapping a few growing tumors may keep breast cancer drugs working longer
- Can a Two-Drug combo outsmart resistant breast and ovarian cancers?
- Can a platform trial match the right drug combo to each tumor?
- Can a vaccine teach the immune system to fight HER2-Positive tumors?